| Carcinoma in situ of bladder
Adstiladrin vs Anktiva
Side-by-side clinical, coverage, and cost comparison for carcinoma in situ of bladder.Deep comparison between: Adstiladrin vs Anktiva with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAnktiva has a higher rate of injection site reactions vs Adstiladrin based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Anktiva but not Adstiladrin, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Adstiladrin
Anktiva
At A Glance
Intravesical instillation
Every 3 months
IFN-alpha2b gene therapy
Intravesical instillation
Weekly
IL-15 receptor agonist
Indications
- Carcinoma in situ of bladder
- Carcinoma in situ of bladder
Dosing
Carcinoma in situ of bladder 75 mL at a concentration of 3 x 10^11 vp/mL instilled intravesically once every 3 months via urinary catheter, retained in the bladder for 1 hour; premedication with an anticholinergic is recommended before each instillation.
Carcinoma in situ of bladder - Induction 400 mcg administered intravesically with BCG once weekly for 6 weeks; a second induction course may be administered if complete response is not achieved at month 3.
Carcinoma in situ of bladder - Maintenance 400 mcg administered intravesically with BCG once weekly for 3 weeks at months 4, 7, 10, 13, and 19; for patients with ongoing complete response at month 25 and later, additional instillations once weekly for 3 weeks at months 25, 31, and 37.
Contraindications
- Prior hypersensitivity reactions to interferon alfa or to any component of the product
—
Adverse Reactions
Most common (>10%) Instillation site discharge, fatigue, pyrexia, chills, bladder spasm, micturition urgency, hematuria, dysuria; laboratory abnormalities (>15%): glucose increased, triglycerides increased, creatinine increased, phosphate decreased, hemoglobin decreased
Serious Coronary artery disease, hematuria
Most common (>=15%) increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills, pyrexia
Serious hematuria, cardiac arrest (fatal in 1 patient)
Pharmacology
Non-replicating adenoviral vector-based gene therapy that delivers a transgene encoding human interferon alfa-2b (IFN-alpha2b) to bladder urothelium, resulting in transient local IFN-alpha2b expression with anticipated anti-tumor effects.
IL-15 receptor agonist; binds the heterotrimeric IL-15 receptor complex (gamma-c, beta-c, and IL-15Ralpha subunits) on CD4+ and CD8+ T cells and NK cells, driving proliferation and activation of NK, CD8+, and memory T cells without expanding immunosuppressive Treg cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Adstiladrin
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
Anktiva
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Adstiladrin
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Anktiva
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Adstiladrin
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Anktiva
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$100
Adstiladrin Copay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Anktiva.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AdstiladrinView full Adstiladrin profile
AnktivaView full Anktiva profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.